Hrt Financial LP Cel Sci Corp Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $498,910 - $964,946	-193,376 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $283,333 - $555,131	72,095 Added 59.44%	193,376 $759,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $861,095 - $1.55 Million	121,281 New	121,281 $861,000
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $207,541 - $312,156	-18,782 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$11.69 - $14.54 $219,561 - $273,090	18,782 New	18,782 $239,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $27.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.